{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:30:39Z","timestamp":1772209839919,"version":"3.50.1"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin-converting enzyme 2 is the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for entry into lung cells. Because ACE-2 may be modulated by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk of coronavirus disease 2019 (COVID-19) pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study sought to analyze the association of COVID-19 pneumonia with previous treatment with ACEIs and ARBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 684 consecutive patients hospitalized for suspected COVID-19 pneumonia and tested by polymerase chain reaction assay. Patients were split into two groups, according to whether (group 1, n = 484) or not (group 2, n = 250) COVID-19 was confirmed. Multivariable adjusted comparisons included a propensity score analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 63.6 \u00b1 18.7 years, and 302 patients (44%) were female. Hypertension was present in 42.6% and 38.4% of patients in groups 1 and 2, respectively (P = 0.28). Treatment with ARBs was more frequent in group 1 than group 2 (20.7% vs. 12.0%, respectively; odds ratio [OR] 1.92, 95% confidence interval [CI] 1.23\u20132.98; P = 0.004). No difference was found for treatment with ACEIs (12.7% vs. 15.7%, respectively; OR 0.81, 95% CI 0.52\u20131.26; P = 0.35). Propensity score-matched multivariable logistic regression confirmed a significant association between COVID-19 and previous treatment with ARBs (adjusted OR 2.36, 95% CI 1.38\u20134.04; P = 0.002). Significant interaction between ARBs and ACEIs for the risk of COVID-19 was observed in patients aged &gt; 60 years, women, and hypertensive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that ACEIs and ARBs are not similarly associated with COVID-19. In this retrospective series, patients with COVID-19 pneumonia more frequently had previous treatment with ARBs compared with patients without COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0244349","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T13:41:21Z","timestamp":1608558081000},"page":"e0244349","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-2220","authenticated-orcid":true,"given":"Jean-Louis","family":"Georges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriane","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Cochet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisson","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"De Tournemire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victorien","family":"Monguillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeva","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Prevot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7919","authenticated-orcid":true,"given":"Guillaume","family":"Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9phine","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrsa","family":"Koukabi-Fradelizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Beressi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Laureana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Prost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Livarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"issue":"2","key":"pone.0244349.ref001","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"8","key":"pone.0244349.ref002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"K Kuba","year":"2005","journal-title":"Nat Med"},{"issue":"20","key":"pone.0244349.ref003","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"CM Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"pone.0244349.ref004","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Y Ishiyama","year":"2004","journal-title":"Hypertension"},{"issue":"7047","key":"pone.0244349.ref005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Y Imai","year":"2005","journal-title":"Nature"},{"issue":"10","key":"pone.0244349.ref006","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","volume":"116","author":"R Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"7","key":"pone.0244349.ref007","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cvr\/cvaa096","article-title":"Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications","volume":"116","author":"E Murray","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"4","key":"pone.0244349.ref008","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/eurheartj\/ehi114","article-title":"Myocardial infarction increases ACE2 expression in rat and humans","volume":"26","author":"LM Burrell","year":"2005","journal-title":"Eur Heart J"},{"issue":"19","key":"pone.0244349.ref009","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"IE Sama","year":"2020","journal-title":"Eur Heart J"},{"issue":"23","key":"pone.0244349.ref010","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/092986711796642562","article-title":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome","volume":"18","author":"A Kaparianos","year":"2011","journal-title":"Curr Med Chem"},{"issue":"4","key":"pone.0244349.ref011","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-kappaB pathway","volume":"50","author":"Y Meng","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"pone.0244349.ref012","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1\u20137) or an angiotensin II receptor antagonist","volume":"225","author":"RM Wosten-van Asperen","year":"2011","journal-title":"J Pathol"},{"issue":"1","key":"pone.0244349.ref013","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"J Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"pone.0244349.ref014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/M20-1515","article-title":"Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review","volume":"173","author":"K Mackey","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0244349.ref015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality","volume":"324","author":"EL Fosbol","year":"2020","journal-title":"JAMA"},{"issue":"25","key":"pone.0244349.ref016","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19","volume":"382","author":"G Mancia","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0244349.ref017","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"N Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"25","key":"pone.0244349.ref018","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19","volume":"382","author":"HR Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0244349.ref019","doi-asserted-by":"crossref","first-page":"e4260","DOI":"10.1136\/bmj.e4260","article-title":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","volume":"345","author":"D Caldeira","year":"2012","journal-title":"BMJ"},{"key":"pone.0244349.ref020","unstructured":"WHO. Clinical management of severe acute respiratory infection when novel coronavirus (\u200e\u200e\u200e\u200enCoV)\u200e\u200e\u200e\u200e infection is suspected: interim guidance, 25 January 2020. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/330854 (accessed 15 May 2020)."},{"issue":"6","key":"pone.0244349.ref021","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0244349.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e3283406f57","article-title":"ACE2: more of Ang-(1\u20137) or less Ang II?","volume":"20","author":"CM Ferrario","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"pone.0244349.ref023","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/HJH.0000000000001607","article-title":"Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit","volume":"36","author":"T Deborde","year":"2018","journal-title":"J Hypertens"},{"key":"pone.0244349.ref024","doi-asserted-by":"crossref","first-page":"e57278","DOI":"10.7554\/eLife.57278","article-title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","volume":"9","author":"GP Rossi","year":"2020","journal-title":"Elife"},{"key":"pone.0244349.ref025","unstructured":"De Simone G, Chair, ESC Council on Hypertension, on behalf of the Nucleus Members. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Available from: https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (accessed 19 May 2020)."},{"issue":"2","key":"pone.0244349.ref026","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1148\/radiol.2020200642","article-title":"Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases","volume":"296","author":"T Ai","year":"2020","journal-title":"Radiology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T13:42:00Z","timestamp":1608558120000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244349"}},"subtitle":[],"editor":[{"given":"Muhammad","family":"Adrish","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244349","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.30.20182451","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]}}}